# FDA 483 - UBI Pharma, Inc. - June 06, 2023

Source: https://www.keypedia.com/records/483/ubi-pharma-inc/43190848-e5f1-4e4f-9b4a-33ded6172cff

> FDA 483 for UBI Pharma, Inc. on June 06, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: UBI Pharma, Inc.
- Inspection Date: 2023-06-06
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: UBI Pharma, Inc., a sterile drug manufacturer in Hukou, Taiwan, received a Form 483 with six observations following an inspection from May 25 to June 6, 2023. The observations primarily concern significant deficiencies in aseptic processing validation, microbiological contamination prevention procedures, equipment cleaning and maintenance, employee training, production and process controls, and laboratory record documentation. These issues indicate a lack of adequate controls to ensure the sterility, quality, and purity of drug products.

## Related Documents

- [483 - Unknown Date](https://www.keypedia.com/records/483/ubi-pharma-inc/b39cf96c-6b57-40cf-9438-9ae2289de3b8)
- [483 - 2025-10-06](https://www.keypedia.com/records/483/ubi-pharma-inc/73c00ddf-619f-4e38-ac2a-66a75c35e905)
- [483 - 2025-10-14](https://www.keypedia.com/records/483/ubi-pharma-inc/3a306b84-362f-4c3e-848b-0abc60c4621f)

## Related Officers

- [Investigator](https://www.keypedia.com/people/marcellinus-d-dordunoo/a0e35c24-0cf5-4b11-95ba-1693fa3ecb3a)

Company: https://www.keypedia.com/companies/ubi-pharma-inc/c7dfbd38-5fae-4a48-b959-a3abae44f320

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1